FossellaF., PereiraJ.R., von PawelJ.: Randomized, multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced NSCLC: the TAX 326 Study Group.J Clin Oncol,21: 3016–3024, 2003.
2.
GrallaR.J., RodriguesJ., von PawelJ.: Prospective analysis of quality of life in a randomized, multinational, phase III study comparing docetaxel + either cisplatin or carboplatin with vinorelbine + cisplatin in patients with advanced NSCLC.Proc ASCO,21: abst 1196, 2002.
3.
BetticherD.C., SchmitzS.F., TotschM.: Mediastinal lymphnode clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 NSCLC: a multicenter phase II trial.J Clin Oncol,21: 1752–1759, 2003
4.
PaccagnellaA., OrlandoA., MarchioniC.: Phase III trial of initial chemotherapy in stage III-IV head and neck cancer: a study by the Gruppo di Studio sui Tumori della Testa e del Collo.J Natl Cancer Inst,86: 265–272, 1994.
5.
ZoratP.L., LoreggianL., PaccagnellaA.: Randomized phase III trial of neoadjuvant chemotherapy in H&N cancer patients: an update based on 10 years’ follow-up.Proc ASCO,23: abst 553, 2004.
6.
PignonJ.P., BourhisJ., DomengeC.: Chemotherapy added to locoregional treatment for H&N squamous cell carcinoma: 3 meta-analysis of updated individual data. MACH-NC collaborative group meta-analysis of chemotherapy on H&N cancer.Lancet,355: 949–955, 2000.
7.
VermorkenJ.B., RemenarE., van HerpenC.: Standard PF vs TPF as neoadjuvant chemotherapy for non resectable locally advanced squamous cell carcinoma of the H&N: a phase III trial of the EORTC H&N cancer group (EORTC #24971).Proc ASCO,23: abst 5508, 2004.
8.
RavdinP., ErbanJ., OvermoyerB.: Phase III comparison of docetaxel and paclitaxel in patients with metastatic breast cancer.Eur J Cancer,1(suppl. 5): S201, 2003.
9.
JonesS., ErbanJ., OvermoyerB.: Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer.Breast Cancer Res Treat,82(suppl. 1): S9 (AIO), 2003.
10.
BontenbalM., BraunJ.J., CreemersG.J.: Phase III study comparing AT to FAC as first-line chemotherapy in patients with metastatic breast cancer.Eur J Cancer,1(suppl. 5): S201 (A671), 2003.
11.
O'ShaughnessyJ., MilesD., VukeljaS.: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.J Clin Oncol,20: 2812–2823, 2002.
12.
ExtraJ.M., CognettiF., MaraninchiD.: Trastuzumab plus docetaxel vs docetaxel alone as first line treatment of HER2-positive metastatic breast cancer: results of a randomised multicentre trial.Eur J Cancer, 2 (Suppl):125(A 239), 2004.
13.
MartinM., PienkowskiT., MackeyJ.: TAC improves disease-free survival and overall survival over FAC in node-positive early breast cancer patients, BCIRG 001: 55 months follow-up.San Antonio Breast Cancer Symposium, A43, 2003.
14.
JonesS.E., SabvinM.A., AsmarL.: Three year results of a prospective randomised trial of adjuvant chemotherapy for patients with stage I-III operable invasive breast cancer comparing 4 courses of AC to 4 courses of TC.Proc ASCO,22: abst 59, 2003.
15.
SmithI.C., HeysS.D., HutcheonA.W.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.J Clin Oncol,20: 1456–1466, 2002.
16.
HutcheonA.W., HeysS.D., SarkarT.K.: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial.Breast Cancer Res Treat,82(suppl. 1): S9 (A 11), 2003.
17.
BearH.D., AndersonS., BrownA.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from NSABP B27.J Clin Oncol,21: 4165–4174, 2003.
18.
JackischC., von MinckwitzG., RaabG.: Primary endpoint analysis of the Geparduo study: preoperative chemotherapy comparing dose-dense vs sequential AT combination in operable breast cancer.Breast Cancer Treat Res,76: S90 (A152), 2002.
19.
von MinckwitzG., RaabG., BlohmerJ.U.: In vivo chemosensitivity-adapted neoadjuvant chemotherapy (TAC followed by vinorelbine-capecitabine salvage therapy) in patients with primary breast cancer: results of the GEPARTRIO randomized pilot study.Breast Cancer Treat Res,82(suppl. 1): S54 (A236) 2003.
TannockI.F., OsobaD., StockierR.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.J Clin Oncol,14: 1756–1764, 1996.
22.
KantoffP.W., HalabiS., ConawayM.: Hydrocortisone with or with out mitoxantrone in men with hormone-refractory prostate cancer: results of a CALGB 9182 study.J Clin Oncol,17: 2506–2513, 1999.
23.
TannockI.F., de WitR., BerryW.R.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med,351: 1502–1512, 2004.
24.
PetrylakD.P., TangenC.M., HussainM.H.A.: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med,351: 1513–1520, 2004.
25.
Van CutsemE., MoiseyenkoV., TjulandinS.: Docetaxel, cisplatin and 5-fluorouracil compared to cisplatin and 5-fluorouracil for chemotherapy-naïve patients with metastatic or locally recurrent unresectable gastric carcinoma: interim results of a randomised phase III trial (V325).Eur J Cancer;1: S20 (A51), 2003.
26.
RothA.D., MaibachR., FalkS.: Docetaxel, cisplatin-5FU vs docetaxel-cisplatin vs epirubicin-cisplatin-5FU as systemic treatment for advanced gastric carcinoma: a randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK).Proc ASCO,23: abst 4020, 2004.
